EPCAM and cancer: Together, these findings suggest that EpCAM-ReTARGTPRIFNαR149A has direct antiproliferative activity towards cancer cells and simultaneously promotes anticancer capacity, cytokine production, and the viability of TPR-specific CD8pos T cells.